The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study

Hematological Oncology
Xingnong YeJian Huang

Abstract

To determine the incidence, risk factors, and relative survival of acute myeloid leukemia (AML) secondary to myelodysplastic syndrome (MDS) in the Surveillance, Epidemiology, and End Results (SEER) database. Retrospective analysis of all patients with new MDS onset in the SEER-18 database from 2001 to 2013. We identified 36 558 patients with primary MDS. The rate of secondary AML (sAML) was 3.7% among patients 40 years or younger and 2.5% among those older than 40 (P = .039). The median transformation interval was significantly shorter for the younger group (4.04 vs 13.1 mo; P < .001). For both age groups, median overall and cancer-specific survival were significantly longer for patients who did not develop sAML. Although the younger patients survived longer than the older patients, sAML development had a more negative effect on the survival of younger patients. Female sex, age, and World Health Organization (WHO) type MDS with single lineage dysplasia (MDS-SLD) were associated with a decreased risk of sAML for older but not younger patients. Among older patients with MDS, a married status, Black race, female sex, shorter time to sAML, and WHO type MDS-SLD or MDS with ringed sideroblasts were favorable prognostic factors for su...Continue Reading

References

Mar 3, 2004·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Alberto OrfaoJesus San Miguel
Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea KuendgenUlrich Germing
Aug 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stuart L GoldbergMarianne Laouri
Apr 29, 2011·Demography·Michael S RendallHilary Waldron
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ayal A AizerPaul L Nguyen
Jan 7, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Avinash G DinmohamedMojca Jongen-Lavrencic
Mar 19, 2014·Journal of Geriatric Oncology·Christoph BammerReinhard Stauder
Aug 5, 2014·Journal of Epidemiology·Dai ChiharaKeitaro Matsuo
Aug 30, 2014·Experimental Hematology & Oncology·Ashwin SridharanAmit K Verma
Mar 5, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·Peter L GreenbergUNKNOWN National comprehensive cancer network
Jul 3, 2015·Current Hematologic Malignancy Reports·Christopher R Cogle
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lene Sofie Granfeldt ØstgårdJan Maxwell Nørgaard
Sep 18, 2015·Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology·Özlen BektaşYahya Büyükaşık
Dec 8, 2015·Hematology·Daniel A Arber, Robert P Hasserjian
Mar 31, 2016·Annals of Hematology·Kathrin NachtkampUlrich Germing
Nov 20, 2016·American Journal of Hematology·Meritxell NomdedeuUNKNOWN Spanish MDS Group

❮ Previous
Next ❯

Citations

Jul 31, 2020·Medicina·Yuliya Andreevna VeryaskinaIgor Fyodorovich Zhimulev

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Software Mentioned

IPSS
R
SPSS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.